Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.
The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | -1.33 Increased by +3.62% | -1.14 Decreased by -16.67% |
| Feb 27, 24 | -1.38 Increased by +4.83% | -0.97 Decreased by -42.27% |
| Nov 2, 23 | -1.35 Increased by +11.18% | -0.74 Decreased by -82.43% |
| Aug 3, 23 | -1.34 Decreased by -482.61% | -1.15 Decreased by -16.52% |
| May 4, 23 | -1.38 Decreased by -35.29% | -1.20 Decreased by -15.00% |
| Mar 1, 23 | -1.45 Decreased by -302.78% | -1.21 Decreased by -19.83% |
| Nov 3, 22 | -1.52 Decreased by -60.00% | -1.17 Decreased by -29.91% |
| Aug 4, 22 | -0.23 Increased by +73.26% | -1.02 Increased by +77.45% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 378.00 K Decreased by -84.97% | -129.42 M Increased by +26.54% | Decreased by -34.24 K% Decreased by -388.77% |
| Jun 30, 23 | 867.00 K Decreased by -99.03% | -128.64 M Decreased by -347.18% | Decreased by -14.84 K% Decreased by -45.79 K% |
| Mar 31, 23 | 4.61 M Increased by +301.83% | -129.44 M Decreased by -28.12% | Decreased by -2.81 K% Increased by +68.12% |
| Dec 31, 22 | 1.96 M Decreased by -96.48% | -131.46 M Decreased by -330.03% | Decreased by -6.72 K% Decreased by -12.12 K% |
| Sep 30, 22 | 2.52 M Decreased by -53.74% | -176.18 M Decreased by -131.55% | Decreased by -7.01 K% Decreased by -400.58% |
| Jun 30, 22 | 88.97 M Increased by +3.03 K% | -28.77 M Increased by +53.27% | Decreased by -32.33% Increased by +98.51% |
| Mar 31, 22 | 1.15 M Decreased by -82.47% | -101.03 M Decreased by -114.49% | Decreased by -8.80 K% Decreased by -1.12 K% |
| Dec 31, 21 | 55.60 M Increased by +727.13% | -30.57 M Increased by +30.41% | Decreased by -54.98% Increased by +91.59% |